Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Bogert

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Alzheimer'S Disease : JAD|February 4, 2017
BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy ParticipantsMaarten Timmers, Soraia Barão, Bianca Van Broeck, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitorMaarten Timmers, Bianca Van Broeck, Steven Ramael, et al.
JAMA Neurology|January 19, 2021
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical TrialReisa Sperling, David Henley, Paul S Aisen, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Alzheimer'S Disease : JAD|February 4, 2017
BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy ParticipantsMaarten Timmers, Soraia Barão, Bianca Van Broeck, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitorMaarten Timmers, Bianca Van Broeck, Steven Ramael, et al.
JAMA Neurology|January 19, 2021
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical TrialReisa Sperling, David Henley, Paul S Aisen, et al.
Pageof 2